LLY

Lilly Eli & Co

1,105.00

-21.80-1.93%

After Hours: 1103.63 -1.38 -0.12%19:59 05/29 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE1,102.45/1,078.78

TODAY RANGE1,101.62-1,140.46

VOL2.72M

MARKET CAP1.06T

52 WEEK RANGE619.40-1,149.10

AVG VOL (3M)3.10M

% TURNOVER0.29%

TURNOVER--

P/E (TTM)39.92

% RANGE3.60%

EPS(TTM)28.15

P/E(FORWARD)31.77

P/B33.99

BVPS33.07

DIVIDEND6.92

P/S16.29

BETA--

DIV YIELD0.62%

FREE FLOAT MKT CAP1.06T

SHARES OUTSTANDING941.74M

NEXT EARNINGS02/04-02/09

FREE FLOAT939.73M

LOT SIZE1

EX-DATE05/15/2026

News

Press Releases

Financial Reports

Profile

TipRanks·1h ago
Acting FDA head vows to block political interference, Endpoint News says
TipRanks·2h ago
Lilly’s ATTAIN-MAINTAIN Trial: A Fresh Pill-Based Play in the Obesity Market
Benzinga·3h ago
Weight Watchers Broadens GLP-1 Reach As Eli Lilly Pursues New Kidney Disease Therapies
Seeking Alpha·6h ago
SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For June 2026
Dow Jones·6h ago
Weight Watchers Expands Reach Through LillyDirect
Benzinga·7h ago
WW International, Affiliated Medical Groups Now Accessible Through Eli Lilly's LillyDirect
TipRanks·8h ago
VOO Hits $1 Trillion — But These 3 Vanguard ETFs Could Outperform with 20%+ Upside
TipRanks·18h ago
Leerink Partners Sticks to Their Buy Rating for Eli Lilly & Co (LLY)
Seeking Alpha·19h ago
RiverPark Long/Short Opportunity Fund Q1 2026 Key Contributors And Detractors
Seeking Alpha·1d ago
Lilly halving planned €2.3B investment in Germany: CEO
Simply Wall St·1d ago
Assessing Eli Lilly (LLY) Valuation As Obesity Drug Hopes Meet Premium Pricing Concerns
TipRanks·1d ago
Lilly’s TRIUMPH-1 Retatrutide Trial Reaches Key Milestone in Obesity Drug Race
TipRanks·1d ago
Lilly’s Pediatric Ulcerative Colitis Trial Marks Key Step for Mirikizumab Growth
NASDAQ·1d ago
1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't
NASDAQ·1d ago
OCGN's Catalyst Calendar for Trial Data and Filings Through 2028

Same Industry

Name/Symbol

Change%

Price

Lilly Eli & Co

LLY

-1.93%

McKesson

MCK

+0.05%

735.17

BIIB

Amgen Inc

AMGN

-0.19%

328.51

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

+8.50%

0.1098

SHPG

CELG

TXMD

Johnson & Johnson

JNJ

+2.29%

228.35

Abbvie Inc

ABBV

-0.42%

217.72

ZTS

GILD

Novo-Nordisk A/S

NVO

-2.61%

42.92

Bristol-Myers Squibb Co

BMY

-3.90%

54.95

ALXN

PFE

Sanofi FR

SNY

+4.65%

44.34

GCVRZ

NVS

RDY

GSK

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.